- Home
- BORR vs NRIX Comparison
BORR vs NRIX Comparison
Compare BORR & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BORR
- NRIX
- Stock Information
- Founded
- BORR 2016
- NRIX 2009
- Country
- BORR Bermuda
- NRIX United States
- Employees
- BORR N/A
- NRIX N/A
- Industry
- BORR Oil & Gas Production
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- BORR Energy
- NRIX Health Care
- Exchange
- BORR Nasdaq
- NRIX Nasdaq
- Market Cap
- BORR 941.4M
- NRIX 1.1B
- IPO Year
- BORR 2019
- NRIX 2020
- Fundamental
- Price
- BORR $1.84
- NRIX $9.50
- Analyst Decision
- BORR Buy
- NRIX Strong Buy
- Analyst Count
- BORR 1
- NRIX 17
- Target Price
- BORR $9.00
- NRIX $30.71
- AVG Volume (30 Days)
- BORR 5.1M
- NRIX 955.7K
- Earning Date
- BORR 05-21-2025
- NRIX 04-08-2025
- Dividend Yield
- BORR 4.32%
- NRIX N/A
- EPS Growth
- BORR 255.56
- NRIX N/A
- EPS
- BORR 0.32
- NRIX N/A
- Revenue
- BORR $1,010,600,000.00
- NRIX $56,417,000.00
- Revenue This Year
- BORR $8.35
- NRIX $15.73
- Revenue Next Year
- BORR $6.39
- NRIX N/A
- P/E Ratio
- BORR $5.78
- NRIX N/A
- Revenue Growth
- BORR 30.98
- NRIX N/A
- 52 Week Low
- BORR $1.62
- NRIX $8.18
- 52 Week High
- BORR $7.26
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- BORR 47.27
- NRIX 35.33
- Support Level
- BORR $1.64
- NRIX $9.02
- Resistance Level
- BORR $1.79
- NRIX $11.56
- Average True Range (ATR)
- BORR 0.12
- NRIX 0.61
- MACD
- BORR 0.02
- NRIX -0.07
- Stochastic Oscillator
- BORR 57.89
- NRIX 14.29
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.